|Bid||0.00 x N/A|
|Ask||0.00 x N/A|
|Day's range||38.38 - 39.95|
|52-week range||38.38 - 39.95|
|Beta (5Y monthly)||1.95|
|PE ratio (TTM)||N/A|
|Earnings date||05 Aug 2021 - 10 Aug 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Not too big, but not too small: The statement is reminiscent of the story about Goldilocks and the three bears, but it's also a pretty good description of mid-cap stocks in the biotech space. In this Motley Fool Live video recorded on July 14, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss five mid-cap healthcare stocks you'll want on your radar for the second half of this year. Keith Speights: Brian, we talked last week about large-cap stocks for investors to watch in the second half of this year.
The big shareholder groups in Editas Medicine, Inc. ( NASDAQ:EDIT ) have power over the company. Generally speaking, as...
After rallying on the coattails of Intelllia's breakthrough, these companies have given back their June gains.